- KR₩82bn
- KR₩77bn
- KR₩55bn
- 53
- 49
- 49
- 49
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.94 | ||
| Price to Tang. Book | 2.06 | ||
| Price to Free Cashflow | 24.88 | ||
| Price to Sales | 1.49 | ||
| EV to EBITDA | 10.31 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.61% | ||
| Return on Equity | 14.18% | ||
| Operating Margin | 11.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | n/a | n/a | 43,171.23 | 48,498.3 | 55,102 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +32.25 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
C&R Research Inc is a Korea-based company is mainly engaged in the clinical trial agency and drug development business. The Company is mainly engaged in the provision of comprehensive early-stage clinical services in the areas of medical writing, regulatory matters, data management, biostatistics and others. The Company is mainly engaged in the provision of consulting services including initial clinical development, clinical trial development, global clinical trial development and others. In addition, the Company is also engaged in the operation of clinical trial training center.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 18th, 2020
- Public Since
- September 23rd, 2020
- No. of Shareholders
- 4,180
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Korea Exchange - KOSDAQ- Shares in Issue
- 54,921,792
- Address
- C&R Bldg., 412, Yeoksam-ro, Gangnam-gu, SEOUL, 06199
- Web
- http://www.cnrres.com/
- Phone
- +82 262511500
- Auditors
- Woori Accountants
Upcoming Events for 359090
Similar to 359090
ABion
Korea Exchange - KOSDAQ
ABL Bio
Korea Exchange - KOSDAQ
ADM Korea
Korea Exchange - KOSDAQ
Amicogen
Korea Exchange - KOSDAQ
AprilBio Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 19:06 UTC, shares in C&R Research are trading at KR₩1,492. This share price information is delayed by 15 minutes.
Shares in C&R Research last closed at KR₩1,492 and the price had moved by +26.63% over the past 365 days. In terms of relative price strength the C&R Research share price has outperformed the FTSE Developed Asia Pacific Index by +27.51% over the past year.
There is no consensus recommendation for this security.
C&R Research does not currently pay a dividend.
C&R Research does not currently pay a dividend.
C&R Research does not currently pay a dividend.
To buy shares in C&R Research you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩1,492, shares in C&R Research had a market capitalisation of KR₩82bn.
Here are the trading details for C&R Research:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 359090
Based on an overall assessment of its quality, value and momentum C&R Research is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like C&R Research. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +16.01%.
As of the last closing price of KR₩1,492, shares in C&R Research were trading +18.72% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The C&R Research PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩1,492.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on C&R Research's directors